Definium Therapeutics Q2 Net Loss $159M; Raises $805M in Equity
Definium Therapeutics reported a net loss of $159.0 million for the second quarter of 2026, with a basic net loss per share of $1.44. For the six months ended June 30, 2026, the net loss was $236.1 million. The company significantly bolstered its financial position by raising approximately $805.0 million in gross proceeds from an equity offering in June 2026, increasing cash and cash equivalents to $655.3 million. Operating expenses rose, driven by increased research and development and general and administrative costs, reflecting the advancement of its four Phase 3 clinical studies.
Key Highlights
- Net loss for Q2 2026 was $159.0 million, compared to $42.7 million in Q2 2025.
- Basic net loss per share for Q2 2026 was $1.44, compared to $0.50 in Q2 2025.
- Cash and cash equivalents increased to $655.3 million as of June 30, 2026, from $257.8 million at year-end 2025.
- Proceeds from equity offerings totaled $805.0 million for the six months ended June 30, 2026.
- Research and development expenses for the six months ended June 30, 2026, were $90.1 million, up from $53.2 million in 2025.
- General and administrative expenses for the six months ended June 30, 2026, were $44.1 million, up from $19.9 million in 2025.
- Accrued clinical trial costs increased due to advancement of four Phase 3 clinical studies.
- Total shareholders' equity increased to $918.7 million from $332.3 million at year-end 2025.
Price Impact
More from DFTX
Definium Therapeutics Announces Positive Phase 3 GAD Trial Results for DT120 ODT
Definium Therapeutics Reports Positive Phase 3 MDD Results; Q2 Net Loss $159M
Definium Therapeutics Raises $758M Net in Upsized Public Offering